PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Stock Information for PainReform Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PainReform Ltd.

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
PainReform Commences Development for OcuRing(TM)-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis
PainReform's DeepSolar, Developing "DeepSolar Predict" within the NVIDIA Connect Program, Featured in The Market Link's "Watchlist Interview" and Announces Progress Toward Pilot Projects
PainReform Provides Business Update for the Six Months Ended June 30, 2025
PainReform/DeepSolar Accepted into NVIDIA Connect Program
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.